|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1990-10-17
|
|
pubmed:abstractText |
C57BL/6 mice are protected from a lethal pneumonia caused by Sendai virus when treated with low doses of mAb directed to the CD3 Ag. The protective mechanism is not due to an accelerated Sendai virus-specific Th cell, CTL, or antibody response but to a strong NK cell response via the in vivo induction of lymphokines. Antibodies directed against the NK1.1 and asialo GM1 marker totally reversed the protective effect of anti-CD3 treatment. In vivo treatment with rIL-2 also induced NK activity and induced antiviral protection. Treatment with anti-CD3 protects when given in a narrow time window (1 day before until 1 day after Sendai virus inoculation), indicating that NK activity is protective in the early phase of virus infection.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
145
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2254-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:2168920-Animals,
pubmed-meshheading:2168920-Antibodies, Monoclonal,
pubmed-meshheading:2168920-Antibodies, Viral,
pubmed-meshheading:2168920-Antigens, CD3,
pubmed-meshheading:2168920-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:2168920-Cytotoxicity, Immunologic,
pubmed-meshheading:2168920-Immunity, Cellular,
pubmed-meshheading:2168920-Immunotherapy,
pubmed-meshheading:2168920-Interleukin-2,
pubmed-meshheading:2168920-Killer Cells, Natural,
pubmed-meshheading:2168920-Lymphocyte Activation,
pubmed-meshheading:2168920-Mice,
pubmed-meshheading:2168920-Mice, Inbred Strains,
pubmed-meshheading:2168920-Parainfluenza Virus 1, Human,
pubmed-meshheading:2168920-Paramyxoviridae Infections,
pubmed-meshheading:2168920-Receptors, Antigen, T-Cell,
pubmed-meshheading:2168920-Survival Analysis,
pubmed-meshheading:2168920-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:2168920-Time Factors
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells.
|
|
pubmed:affiliation |
Division of Immunology, The Netherlands Cancer Institute, Amsterdam.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
